Deloitte recognise IgniteData in ‘The future of pharma services’ M&A Report

The following extract is take from Deloitte’s M&A Report on The Future of Pharma Service.

Advancements in data science are significantly shortening timeframes for clinical trials, enabling faster drug approvals and improving chances for success. This represents a crucial step given that as soon as a patient is established the clock is ticking for businesses to finish development, complete regulatory approvals, and move on to manufacturing and commercialisation.

In addition to M&A centred around harnessing RWE to ensure trials are more effective, there will soon be a focus on process automation, enabling repetitive and costly steps to be conducted quickly. Clinical trials depend upon finding the right patients and retaining them. The specialist firms marketing themselves as dramatically improving this process, by using rich and complete data, will be attractive acquisition targets.

Among the businesses innovating extensively is UK-based IGNITE DATA, whose core activity is accessing Electronic Health Records (EHR) and matching the right patient to specific studies, with anonymised information.

During trials, information from health records is typically entered into electronic data capture (EDC) systems, manual work that is often laborious and has to be checked for errors. IGNITE DATA is exploring how to solve this problem by plumbing data from digital health records directly into EDC systems, improving accuracy and speeding trial processes. This improves the return on investment for drug and medical device developers, whilst care locations that implement these practices can increase income by marketing themselves as highly efficient places to conduct trials. IGNITE DATA is leading part of a UK government (Innovate UK) part-funded project exploring the potential of the technology to ultimately improve treatment availability.

Read and download the full report.